Interview with Sheila Kelly, Chief Executive, Proprietary Association of Great…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed…
Proprietary Association of Great Britain (PAGB)
Last updated: 13.02.2014
Address: PAGB, Vernon House, Sicilian Avenue, London , WC1A 2QS, United Kingdom
Tel: +44 (0)20 7242 8331
Company description
PAGB is the UK trade association for manufacturers of branded over-the-counter medicines and food supplements.
Over-the-counter is the term used for medicines that can be bought in pharmacies and in other retail outlets without a prescription. Some of the medicines can only be sold in pharmacies and pharmacists are required to supervise their sales and ask questions before supplying them to customers.
Products and services
Established in 1919, the association was founded to promote responsible consumer healthcare by controlling the advertising of all the medicines of the companies in membership through a code of advertising practice. This remains a core activity for the association although the PAGB Medicines Advertising Code now sits within a legal framework.
For more than 20 years, PAGB’s research and policy development has focused on framing self care as a level of care in the NHS and its policies.
The Department of Health publication ‘Self care – A real choice, Self care support – a practical option’ (2005) defines self care as:
‘…the actions people take for themselves, their children and their families to stay fit and maintain good physical and mental health; meet social and psychological needs; prevent illness or accidents; care for minor ailments and long-term conditions; and maintain health and wellbeing after an acute illness or discharge from hospital.’
Interviews
Related
M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Opinion / 3 Ways the UK’s Pharma Sector is Driving Innovation
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
News Roundup / UK Pharma May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
Coronavirus / GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
The UK / The G7’s Hottest Life Science Investment Destination?
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Biotech Funding / 2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
Cannabis / GW Pharma's CBD Drug Profits Soar in 2nd Quarter 2019
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Amryt: A Rare Disease Startup Going Global
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…
